{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:26:24Z","timestamp":1785446784295,"version":"3.56.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite advances in anti-HER2 therapies leading to high pathological complete response (pCR) rates, the blood-brain barrier (BBB) still shelters micrometastatic deposits, so intracranial relapse continues to pose a formidable therapeutic obstacle in HER2-positive breast cancer (BC). Understanding the mechanisms underlying early central nervous system (CNS) relapse and integrating BBB-penetrant strategies remain urgent unmet needs. We report a 60-year-old woman with HER2-positive, hormone receptor-negative breast cancer who achieved pCR after neoadjuvant docetaxel combined with trastuzumab and pertuzumab, followed by 12 months of maintenance trastuzumab and pertuzumab. Despite achieving pCR and comprehensive systemic control, the patient developed multifocal brain metastases two months after completing maintenance therapy, without extracranial recurrence. This case underscores the limitations of large-molecule monoclonal antibodies in preventing CNS recurrence due to poor BBB permeability, allowing dormant CNS-adapted clones to persist and later expand. Emerging CNS-active therapies, including small-molecule tyrosine kinase inhibitors (TKIs) such as tucatinib and next-generation antibody-drug conjugates (ADCs) like trastuzumab deruxtecan, have shown promising intracranial activity. In addition, advanced strategies such as intensified MRI surveillance, radiomics, liquid biopsy, focused ultrasound-mediated BBB disruption, nanoparticle delivery systems, and radionuclide therapy offer potential avenues for early identification and prevention of cerebral metastases.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1668995","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:43:52Z","timestamp":1767599032000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Pathological complete response yet early brain relapse in HER2-positive breast cancer: a case-based review"],"prefix":"10.3389","volume":"16","author":[{"given":"Jing","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanli","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2023.03.007","article-title":"Risk of recurrence in patients with HER2+ Early-stage breast cancer: literature analysis of patient and disease characteristics","volume":"23","author":"O\u2019Shaughnessy","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5021","article-title":"Breast cancer brain metastasis: Current evidence and future directions","volume":"12","author":"Sun","year":"2023","journal-title":"Cancer Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112908","article-title":"Modern management and diagnostics in HER2+ Breast cancer with CNS metastasis","volume":"15","author":"Warrior","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro-oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e193692","DOI":"10.1001\/jamaoncol.2019.3692","article-title":"Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in asia: the PEONY phase 3 randomized clinical trial","volume":"6","author":"Shao","year":"2020","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years\u2019 Follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41523-022-00380-7","article-title":"Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab","volume":"8","author":"Ferraro","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.177076","article-title":"Targeting HER2 in breast cancer with brain metastases: A pharmacological point of view with special focus on the permeability of blood-brain barrier to targeted treatments","volume":"985","author":"Guglielmi","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920953729","article-title":"Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review","volume":"12","author":"Chan","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1918819","article-title":"Collecting antibodies and large molecule biomarkers in mouse interstitial brain fluid: a comparison of microdialysis and cerebral open flow microperfusion","volume":"13","author":"Le Prieult","year":"2021","journal-title":"Mabs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1208\/s12248-022-00701-5","article-title":"Effect of the size of protein therapeutics on brain pharmacokinetics following systematic administration","volume":"24","author":"Chang","year":"2022","journal-title":"AAPS J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13036-023-00352-w","article-title":"Breast cancer brain metastasis: from etiology to state-of-the-art modeling","volume":"17","author":"Farahani","year":"2023","journal-title":"J Biol Eng"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512034","article-title":"Navigating the blood\u2013brain barrier: challenges and therapeutic strategies in breast cancer brain metastases","volume":"24","author":"Terceiro","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41523-024-00631-9","article-title":"Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab","volume":"10","author":"Chew","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41392-022-00872-9","article-title":"Targeting polarized phenotype of microglia via IL6\/JAK2\/STAT3 signaling to reduce NSCLC brain metastasis","volume":"17","author":"Farahani","year":"2022","journal-title":"Signal Transduction Targeted Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/cells14100707","article-title":"Unlocking the role of metabolic pathways in brain metastatic disease","volume":"14","author":"Pinto","year":"2025","journal-title":"Cells"},{"key":"B21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/neuonc\/noae219","article-title":"The immune landscape in brain metastasis","volume":"27","author":"Schreurs","year":"2025","journal-title":"Neuro-oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0405","article-title":"Mechanistic modeling of central nervous system pharmacokinetics and target engagement of HER2 tyrosine kinase inhibitors to inform treatment of breast cancer brain metastases","volume":"28","author":"Li","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B23","unstructured":"Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab&x2F;Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib\n          \n          \n            \n              Anders\n              C\n            \n          \n          \n          2025"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00716-6","article-title":"Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial","volume":"23","author":"Yan","year":"2022","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae123","article-title":"Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases","volume":"26","author":"Bartsch","year":"2024","journal-title":"Neuro-oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"NEJMoa2508668","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","author":"Tolaney","year":"2025","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial\u2606","volume":"31","author":"Montemurro","year":"2020","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0753","article-title":"Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib\/placebo in patients with residual HER2-positive invasive breast cancer","volume":"17","author":"O\u2019Sullivan","year":"2021","journal-title":"Future Oncol"},{"key":"B30","unstructured":"A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in participants with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy (DESTINY-breast05)\n          \n          \n            \n              Sankyo\n              D\n            \n          \n          \n          2025"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S347","DOI":"10.1016\/j.annonc.2024.08.2169","article-title":"318TiP Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in stage II-III HER2-positive breast cancer: The TRAIN-4 study","volume":"35","author":"Louis","year":"2024","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-025-01983-4","article-title":"Biological profile of breast cancer brain metastasis","volume":"13","author":"Liu","year":"2025","journal-title":"Acta Neuropathol Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110379","article-title":"Brain metastasis risk prediction model in females with hormone receptor-positive breast cancer","volume":"197","author":"Cacho-D\u00edaz","year":"2024","journal-title":"Radiother Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_2079_21","article-title":"Risk factors and prognostic factors of brain metastasis of triple-negative breast cancer: A single-center retrospective study","volume":"20","author":"He","year":"2024","journal-title":"J Canc Res Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12964-023-01183-4","article-title":"Anoikis resistance\u2014-protagonists of breast cancer cells survive and metastasize after ECM detachment","volume":"21","author":"Dai","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","article-title":"The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis","volume":"15","author":"Huang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"14736","DOI":"10.1038\/s41598-025-99685-3","article-title":"GRB2 promotes brain metastasis in HER2-positive breast cancer by regulating the Ras\/MAPK pathway","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112780","article-title":"Molecular mechanisms of cancer-induced sleep disruption","volume":"20","author":"Walker","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41420-025-02469-x","article-title":"ANXA2 in cancer: aberrant regulation of tumor cell apoptosis and its immune interactions","volume":"11","author":"Huang","year":"2025","journal-title":"Cell Death Discov"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1162089","article-title":"Small extracellular vesicles in breast cancer brain metastasis and the prospect of clinical application","volume":"11","author":"Luo","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1585668","article-title":"Molecular mechanisms and signaling pathways related to brain metastasis in breast cancer","volume":"16","author":"Liang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102748","article-title":"Androgen receptor is expressed in the majority of breast cancer brain metastases and is subtype-dependent","volume":"15","author":"Fan","year":"2023","journal-title":"Cancers"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1383809","article-title":"From metabolism to Malignancy: the multifaceted role of PGC1\u03b1 in cancer","volume":"14","author":"Wang","year":"2024","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0621","article-title":"The role of PGC1\u03b1 in cancer metabolism and its therapeutic implications","volume":"15","author":"Tan","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1186\/s12885-025-14095-y","article-title":"Novel insight of critical genes involved in breast cancer brain metastasis: evidence from a cross-tissue transcriptome association study and validation through external clinical cohorts","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1038\/s41467-020-18883-x","article-title":"Identification of 31 loci for mammographic density phenotypes and their associations with breast cancer risk","volume":"11","author":"Sieh","year":"2020","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.21037\/gs-21-537","article-title":"A pre-operative MRI-based brain metastasis risk-prediction model for triple-negative breast cancer","volume":"10","author":"Cheng","year":"2021","journal-title":"Gland Surg"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1550\u201358","DOI":"10.1093\/neuonc\/noaf018","article-title":"Phase II trial of brain MRI surveillance in stage IV breast cancer","volume":"6","author":"Ahmed","year":"2025","journal-title":"Neuro-oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102860","article-title":"Expert consensus on the prevention of brain metastases in patients with HER2-positive breast cancer","volume":"132","author":"M\u00fcller","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae066","article-title":"A brain metastasis liquid biopsy: Where are we now","volume":"6","author":"Robinson","year":"2024","journal-title":"Neuro-Oncol Adv"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1436942","article-title":"Crosstalk between breast cancer-derived microRNAs and brain microenvironmental cells in breast cancer brain metastasis","volume":"14","author":"Khan","year":"2024","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04795-z","article-title":"Focused ultrasound-mediated enhancement of blood-brain barrier permeability for brain tumor treatment: a systematic review of clinical trials","volume":"170","author":"Zhu","year":"2024","journal-title":"J Neurooncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"eabj4011","DOI":"10.1126\/scitranslmed.abj4011","article-title":"MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases","volume":"13","author":"Meng","year":"2021","journal-title":"Sci Transl Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34542","article-title":"Nanoparticle drug delivery to target breast cancer brain metastasis: Current and future trends","volume":"153","author":"Kannan","year":"2023","journal-title":"Int J Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41181-023-00208-0","article-title":"225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumor and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts","volume":"8","author":"Kondo","year":"2023","journal-title":"EJNMMI Radiopharm Chem"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.32607\/actanaturae.11611","article-title":"The evolution of targeted radionuclide diagnosis of HER2-positive breast cancer","volume":"14","author":"Bragina","year":"2022","journal-title":"Acta Nat"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1668995\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:43:54Z","timestamp":1767599034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1668995\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2025.1668995"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1668995","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1668995"}}